Free Trial
NASDAQ:CYTH

Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

Cyclo Therapeutics logo
$0.72 0.00 (0.00%)
As of 03/26/2025

About Cyclo Therapeutics Stock (NASDAQ:CYTH)

Key Stats

Today's Range
$0.72
$0.72
50-Day Range
$0.65
$0.80
52-Week Range
$0.55
$1.62
Volume
N/A
Average Volume
445,259 shs
Market Capitalization
$23.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.95
Consensus Rating
Hold

Company Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Cyclo Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

CYTH MarketRank™: 

Cyclo Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 474th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cyclo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cyclo Therapeutics has received no research coverage in the past 90 days.

  • Read more about Cyclo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cyclo Therapeutics are expected to remain at ($0.66) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclo Therapeutics has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cyclo Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for CYTH.
  • Dividend Yield

    Cyclo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cyclo Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CYTH.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cyclo Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    68.55% of the stock of Cyclo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cyclo Therapeutics' insider trading history.
Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTH Stock News Headlines

Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
10 Best Micro Cap Stocks to Buy Now
See More Headlines

CYTH Stock Analysis - Frequently Asked Questions

Cyclo Therapeutics' stock was trading at $0.59 at the start of the year. Since then, CYTH shares have increased by 22.1% and is now trading at $0.7206.
View the best growth stocks for 2025 here
.

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Thursday, August, 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.07. The company earned $0.12 million during the quarter, compared to the consensus estimate of $0.40 million.

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Video Communications (ZM) and Fisker (FSR).

Company Calendar

Last Earnings
8/15/2024
Today
5/01/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTH
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$0.95
High Stock Price Target
$0.95
Low Stock Price Target
$0.95
Potential Upside/Downside
+31.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,060,000.00
Net Margins
-2,847.19%
Pretax Margin
-2,847.30%

Debt

Sales & Book Value

Annual Sales
$870,725.00
Price / Cash Flow
N/A
Book Value
$0.21 per share
Price / Book
3.43

Miscellaneous

Free Float
23,116,000
Market Cap
$23.72 million
Optionable
No Data
Beta
-0.57
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CYTH) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners